Objective: Zinc is a trace element, which has been related to inflammatory diseases such as inflammatory bowel disease (IBD). We aimed to evaluate the serum zinc levels in Iranian patients with Crohn's disease (CD). Materials and methods:The present study was conducted on 65 CD patients and 65 healthy controls. Serum zinc levels were measured in both patients and controls and compared by age, sex, and site of inflammation between groups. Results: Mean serum zinc level in the study population was 86.2±17.0 ng/dL. The serum zinc level was 88.1±16.7 ng/dL in CD patients and 86.2±17.0 ng/dL in the control group. The difference between groups was not statistically significant (P=0.191). No significant differences were observed in serum zinc levels of males and females (P=0.087). Zinc deficiency was observed in 21.5% and 7.7% of cases and controls, respectively. Compared to the control group, low serum zinc levels were significantly higher in CD patients (P=0.025). Regarding the site of inflammation, neither the concentration of serum zinc (P=0.058) nor zinc deficiency prevalence (P=0.864) were significantly different in cases compared to controls. Conclusion: The prevalence of zinc deficiency was higher in CD patients compared to controls. However, serum zinc concentrations were not significantly different between groups. Age, sex, and site of inflammation were not found to be predictors of zinc deficiency. Evaluating the zinc status of CD patients for possible supplementation in cases of deficiency is recommended.
Objective: Zinc is a trace element, which has been related to inflammatory diseases such as inflammatory bowel disease (IBD). We aimed to evaluate the serum zinc levels in Iranian patients with Crohn's disease (CD). Materials and methods:The present study was conducted on 65 CD patients and 65 healthy controls. Serum zinc levels were measured in both patients and controls and compared by age, sex, and site of inflammation between groups. Results: Mean serum zinc level in the study population was 86.2±17.0 ng/dL. The serum zinc level was 88.1±16.7 ng/dL in CD patients and 86.2±17.0 ng/dL in the control group. The difference between groups was not statistically significant (P=0.191). No significant differences were observed in serum zinc levels of males and females (P=0.087). Zinc deficiency was observed in 21.5% and 7.7% of cases and controls, respectively. Compared to the control group, low serum zinc levels were significantly higher in CD patients (P=0.025). Regarding the site of inflammation, neither the concentration of serum zinc (P=0.058) nor zinc deficiency prevalence (P=0.864) were significantly different in cases compared to controls. Conclusion: The prevalence of zinc deficiency was higher in CD patients compared to controls. However, serum zinc concentrations were not significantly different between groups. Age, sex, and site of inflammation were not found to be predictors of zinc deficiency. Evaluating the zinc status of CD patients for possible supplementation in cases of deficiency is recommended.
Authors: Yoo Min Han; Hyuk Yoon; Soo Lim; Mi-Kyung Sung; Cheol Min Shin; Young Soo Park; Nayoung Kim; Dong Ho Lee; Joo Sung Kim Journal: Gut Liver Date: 2017-05-15 Impact factor: 4.519